✦ LIBER ✦

9160 Molecular and clinical biomarkers of outcome with cetuximab: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC)

✍ Scribed by O'Byrne, K.; Pereira, J. Rodrigues; vonPawel, J.; Szczesna, A.; Waller, C.; Barrios, C.; Gatzemeier, U.; Celik, I.; Stroh, C.; Pirker, R.

Book ID: 122414068
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71873-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors in patients with adva

Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study

✍ Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 335 KB

Molecular Predictors of Outcome With Gef

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

✍ Douillard, J.-Y.; Shepherd, F. A.; Hirsh, V.; Mok, T.; Socinski, M. A.; Gervais, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

Molecular Predictors of Outcome With Gef

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer

✍ Hirsch, F. R.; Varella-Garcia, M.; Bunn, P. A.; Franklin, W. A.; Dziadziuszko, R 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 191 KB

Clinical genotyping and efficacy outcome

Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer

✍ Pallaud, Celine; Reck, Martin; Juhasz, Erzsebet; Szima, Barna; Yu, Chung-Jen; Bu 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 405 KB

First-cycle rash and survival in patient

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

✍ Ulrich Gatzemeier; Joachim von Pawel; Ihor Vynnychenko; Petr Zatloukal; Filippo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 220 KB

EGFR expression as a predictor of surviv

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

✍ Robert Pirker; Jose R Pereira; Joachim von Pawel; Maciej Krzakowski; Rodryg Raml 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 872 KB